Pier Capital LLC Has $9.37 Million Stake in Repligen Co. (NASDAQ:RGEN)

Pier Capital LLC increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 65,109 shares of the biotechnology company’s stock after purchasing an additional 766 shares during the quarter. Repligen makes up approximately 1.3% of Pier Capital LLC’s portfolio, making the stock its 22nd largest position. Pier Capital LLC owned about 0.12% of Repligen worth $9,372,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Zions Bancorporation N.A. boosted its stake in shares of Repligen by 48.9% during the 4th quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company’s stock valued at $2,027,000 after buying an additional 4,626 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Repligen during the fourth quarter worth $19,021,000. Vanguard Group Inc. boosted its position in Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock valued at $734,251,000 after purchasing an additional 56,723 shares during the last quarter. LPL Financial LLC grew its stake in Repligen by 47.6% in the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company’s stock valued at $4,873,000 after purchasing an additional 10,395 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Repligen in the 4th quarter worth about $667,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $145.15 on Tuesday. The stock has a market capitalization of $8.15 billion, a PE ratio of -284.61, a P/E/G ratio of 4.54 and a beta of 0.95. The stock has a 50-day simple moving average of $155.91 and a 200 day simple moving average of $148.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $198.00.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Research analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Analyst Ratings Changes

RGEN has been the subject of several recent research reports. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target for the company. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.